Stockscreener 앱 받기
6.41
0.16%
-0.010
시장 영업 전:
6.48
0.07
+1.09%
전일 마감가:
$6.42
열려 있는:
$6.11
하루 거래량:
452.88K
Relative Volume:
1.49
시가총액:
$206.98M
수익:
$4.06M
순이익/손실:
$-50.22M
주가수익비율:
-3.9605
EPS:
-1.6185
순현금흐름:
$-25.37M
1주 성능:
+27.94%
1개월 성능:
+87.43%
6개월 성능:
-13.38%
1년 성능:
+0.00%
1일 변동 폭
$5.9112
$6.55
1주일 범위
$4.71
$6.75
52주 변동 폭
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
명칭
Insight Molecular Diagnostics Inc
전화
949-409-7600
주소
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.41 | 207.30M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 개시 | Lake Street | Buy |
| 2022-05-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-03-17 | 재개 | Needham | Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 개시 | BTIG Research | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Speculative Buy |
| 2020-07-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 개시 | Needham | Buy |
| 2019-02-13 | 개시 | Piper Jaffray | Overweight |
| 2019-01-29 | 업그레이드 | Janney | Neutral → Buy |
| 2018-12-19 | 재개 | Lake Street | Buy |
모두보기
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance
BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Australia
BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com
Insight Molecular Q1 2026 Earnings Call Transcript - Sahm
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate - Sahm
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call H - GuruFocus
Insight Molecular Diagnostics (IMDX) Sees Positive Engagement wi - GuruFocus
Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M - MSN
Insight Molecular Diagnostics (IMDX) Q1 2026 Earnings: EPS not d - GuruFocus
Insight Molecular Diagn 1Q Rev $32,000 >IMDX - Moomoo
Insight Molecular Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Insight Molecular Diagnostics Q1 2026 sees stock rise 2.41% - Investing.com Australia
IMDX Q1 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics Inc Q1 Net Income USD -4.29 Million - TradingView
Insight Molecular Diagn 1Q Loss/Shr 12c >IMDX - Moomoo
Insight Molecular Diagnostics : Investor Deck (imdx investor presentation may 2026) - marketscreener.com
Insight Molecular Diagnostics Q1 loss narrows as costs drop - TradingView
Insight Molecular Diagnostics: Q1 Earnings Snapshot - crossville-chronicle.com
Insight Molecular Diagnostics (NASDAQ: IMDX) Q1 2026 revenue collapses to $32K as losses narrow - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - The Manila Times
[8-K] Insight Molecular Diagnostics Inc. Reports Material Event - Stock Titan
[8-K/A] Insight Molecular Diagnostics Inc. Amends Material Event Report - Stock Titan
Press Release: IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - Moomoo
Insight Molecular Diagnostics Inc. Q1 earnings preview - MSN
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ... By GuruFocus - Investing.com Canada
MSN Money - MSN
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Number of shareholders of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Earnings Preview: IMDX to Report Financial Results Post-market on May 13 - Moomoo
iMDx will post quarterly results May 13, then take investor questions live - Stock Titan
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Pfizer (PFE) and Travere Therapeutics (TVTX) - The Globe and Mail
Insight Molecular Corrects Bylaws Disclosure in Annual Report - TipRanks
IMDX (NASDAQ: IMDX) outlines 2026 proxy votes, FDA dd-cfDNA strategy - Stock Titan
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones - Yahoo Finance
Broadwood Partners, Neal C. Bradsher buy $2.03m of Insight Molecular Diagnostics - Investing.com India
Broadwood and Neal Bradsher hold 39.7% of Insight Molecular (IMDX) shares - Stock Titan
Broadwood entities add 570K IMDX shares, hold 12.7M plus warrants - Stock Titan
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Insight Molecular Diagnostics Inc (IMDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
자본화:
|
볼륨(24시간):